QNCX, US22053A1079

Quince Therapeutics stock faces October 6 vote after board changes

Published on 10/05/2026 at 22:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Quince Therapeutics stock was trading at USD 28.995 on October 5, with a special vote scheduled for October 6. Q2 brought a USD 75.5 million loss.

QNCX, US22053A1079, Illustration mit AI erstellt.

Quince Therapeutics stock (ISIN US22053A1079) was trading at USD 28.995 on Nasdaq at 10:41 a.m. ET on October 5, 2026, down 0.70 percent from the prior close of USD 29.20. The immediate corporate trigger is a special stockholder meeting on October 6, where three proposals could reshape the company’s capital structure and governance.

Three proposals reach a vote

According to StockTitan on October 2, 2026, shareholders will vote on the conversion of Series C preferred stock and related warrants, a minimum-price share issuance proposal, and an increase in authorized common shares from 250.0 million to 275.0 million. The conversion proposal could represent more than 20 percent of the existing common stock and may contribute to a change of control.

The filing also describes conditional board changes. Three directors tendered resignations, while four incoming directors were approved conditionally on October 1, 2026, with the changes taking effect two business days after the meeting if the required proposals pass.

Cash supports the pulmonary pivot

Quince is using the Orphai acquisition to build a pulmonary drug pipeline centered on LAM-001, an inhaled rapamycin candidate for PH-ILD, BOS and SAPH. The company’s investor-relations page says the Phase 2b PH-ILD study is underway, the BOS study is ongoing, and a SAPH study is anticipated in late 2026.

According to StockTitan, second-quarter 2026 included a net loss of USD 75.5 million, or USD 12.31 per share, while cash and cash equivalents stood at USD 116.0 million as of June 30, 2026. The financing produced USD 103.6 million in net proceeds, and management said the cash runway could extend through the end of 2028.

Consensus target stays far higher

MarketBeat lists a Moderate Buy consensus based on 13 analyst ratings. The tally includes 2 sell ratings, 3 hold ratings, 6 buy ratings and 2 strong buy ratings, while the average 12-month target is USD 206.71, with a high of USD 1,000.00 and a low of USD 68.00. Against the USD 28.995 reference price, the average target lies 612.9 percent above the price.

The valuation gap comes with substantial execution risk: the Q2 loss, the pending share-issuance vote and the company’s dependence on Phase 2 development milestones all sit alongside the cash position. For investors, the October 6 vote is the next concrete checkpoint.

QNCX stock trades below USD 29

Quince Therapeutics stock was trading at USD 28.995 on Nasdaq on October 5, 2026, with a market capitalization of USD 29.7 million. The price was 0.70 percent below the prior close, keeping the vote and the LAM-001 development plan at the center of the near-term story.